Arthritis Innovation Corporation (AIC) has licensed the game-changing BEPO® platform technology from MedinCell (Montpellier, France).  This injectable and biodegradable drug delivery system is comprised of the well-known biomaterials Poly-ethyleneglycol (PEG) and Poly-lactic acid (PLA), and forms a semi-solid depot when exposed to an aqueous environment.   

The BEPO® technology is compatible with both hydrophobic and hydrophilic APIs, including small molecules, peptides, proteins and antibodies, and can be modified to provide various release profiles depending on the clinical need.